mrd to assess depth of response in a high-risk myeloma patient
Published 3 years ago • 106 plays • Length 5:46Download video MP4
Download video MP3
Similar videos
-
6:03
mrd-based risk assessment in multiple myeloma to inform maintenance discontinuation
-
6:01
individualizing transplant decisions based on depth of response in myeloma
-
1:33:39
the relevance of mrd assessment in the clinical management of multiple myeloma (mm) patients
-
15:27
depth of response and mrd status in ultra high-risk mm: results of the uk optimum/muknine trial
-
6:19
mrd to motivate a myeloma patient to augment therapy
-
2:07
tiffany: a multiple myeloma patient tells her clonoseq® mrd testing story (2 minute version)
-
9:35
mrd helps predict outcomes and informs maintenance treatment for a myeloma patient
-
1:11:05
the utility of mrd testing for myeloma patient treatment and outcomes
-
4:10
how does minimal residual disease (mrd) testing affect treatment decisions?
-
4:10
where does mrd belong as a tool in myeloma?
-
1:41
dara-rvd, with an mrd-adaptive duration of therapy, in high-risk smoldering myeloma
-
2:34
early mrd negativity predicts depth of response to car t-cells in r/r mm
-
2:11
mrd as a predictor of risk in myeloma
-
57:58
how often should mrd testing occur during remission (and an mrd overview) with dr. joshua richter
-
19:40
mrd evaluation in myeloma: a necessary clinical tool?
-
21:08
mrd evaluation in myeloma: the future is here
-
23:32
approaching mrd in multiple myeloma
-
19:41
multiple myeloma: minimal residual disease
-
48:30
maintenance treatment in myeloma